Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA’s Kweder Among Witnesses At Senate Drug Safety Hearing March 1

This article was originally published in The Pink Sheet Daily

Executive Summary

The Office of New Drugs deputy director could discuss implementation of the new Drug Safety Oversight Board. Other witnesses at the Health Committee hearing include former FDA advisor Gottlieb, Zuckerman Spaeder partner Schultz.

You may also be interested in...



FDA's Woodcock To Testify Before Senate Health Committee March 3

Janet Woodcock is one of two FDA representatives testifying at two days of hearings on issues related to drug safety; Sandra Kweder will testify March 1. Vertex Pharmaceuticals CEO Joshua Boger will present the pharmaceutical industry's point of view.

FDA's Woodcock To Testify Before Senate Health Committee March 3

Janet Woodcock is one of two FDA representatives testifying at two days of hearings on issues related to drug safety; Sandra Kweder will testify March 1. Vertex Pharmaceuticals CEO Joshua Boger will present the pharmaceutical industry's point of view.

FDA Drug Safety Oversight Board Will Include VA, Other Agencies

The panel is the primary feature of FDA's proposal to reform drug safety review within the agency; other features include the creation of a drug safety website. The panel and website are intended to increase drug safety "oversight" and "openness" at FDA.

Topics

UsernamePublicRestriction

Register

LL1133990

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel